Neurovation Labs

Executive Summary

Neurovation Labs is a preclinical-stage biotechnology company pioneering precision medicine for mental health disorders. Based in San Francisco, the company develops region-selective small molecule neuromodulators for central nervous system diseases, with a lead program targeting PTSD. Additionally, Neurovation holds patents for a novel brain imaging device designed to diagnose PTSD via biomarker detection, offering a dual approach to treatment and diagnosis. The company's platform aims to address the significant unmet need in mental health by enabling more targeted therapies with potentially fewer side effects. As a private, preclinical entity, Neurovation Labs represents an early-stage investment opportunity with high risk but also high upside if its lead programs succeed in clinical development.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for PTSD Lead Compound40% success
• Q4 2026FDA Submission for Brain Imaging Device (510(k) or Breakthrough Designation)50% success
• Q3 2026Publication of Preclinical Data in Peer-Reviewed Journal70% success